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Development, implementation 
and outcomes of a quality 
assurance system for the provision 
of continuous renal replacement 
therapy in the intensive care unit
Eloy F. Ruiz1, Victor M. Ortiz‑Soriano1, Monica Talbott1, Bryan A. Klein1, 
Melissa L. Thompson Bastin2, Kirby P. Mayer3, Emily B. Price1, Robert Dorfman1, 
Brandi N. Adams1, Lisa Fryman1, Javier A. Neyra1* on behalf of The University of Kentucky 
CRRT Quality Assurance Group*
Critically ill patients with requirement of continuous renal replacement therapy (CRRT) represent 
a growing intensive care unit (ICU) population. Optimal CRRT delivery demands continuous 
communication between stakeholders, iterative adjustment of therapy, and quality assurance 
systems. This Quality Improvement (QI) study reports the development, implementation and 
outcomes of a quality assurance system to support the provision of CRRT in the ICU. This study was 
carried out at the University of Kentucky Medical Center between September 2016 and June 2019. 
We implemented a quality assurance system using a step‑wise approach based on the (a) assembly 
of a multidisciplinary team, (b) standardization of the CRRT protocol, (c) creation of electronic CRRT 
flowsheets, (d) selection, monitoring and reporting of quality metrics of CRRT deliverables, and (e) 
enhancement of education. We examined 34‑month data comprising 1185 adult patients on CRRT 
(~ 7420 patient‑days of CRRT) and tracked selected QI outcomes/metrics of CRRT delivery. As a result 
of the QI interventions, we increased the number of multidisciplinary experts in the CRRT team and 
ensured a continuum of education to health care professionals. We maximized to 100% the use of 
continuous veno‑venous hemodiafiltration and doubled the percentage of patients using regional 
citrate anticoagulation. The delivered CRRT effluent dose (~ 30 ml/kg/h) and the delivered/prescribed 
effluent dose ratio (~ 0.89) remained stable within the study period. The average filter life increased 
from 26 to 31 h (p = 0.020), reducing the mean utilization of filters per patient from 3.56 to 2.67 
(p = 0.054) despite similar CRRT duration and mortality rates. The number of CRRT access alarms per 
treatment day was reduced by 43%. The improvement in filter utilization translated into ~ 20,000 
USD gross savings in filter cost per 100‑patient receiving CRRT. We satisfactorily developed and 
implemented a quality assurance system for the provision of CRRT in the ICU that enabled sustainable 
tracking of CRRT deliverables and reduced filter resource utilization at our institution.
Continuous renal replacement therapy (CRRT) is the most common modality of renal replacement therapy 
(RRT) utilized for managing critically ill patients with acute kidney injury (AKI) or end-stage kidney disease 
(ESKD) who are hemodynamically unstable and with significant electrolyte/acid–base abnormalities or volume 
 overload1–3. Although only 6–10% of all patients in the intensive care unit (ICU) require acute RRT 4–6, mortality 
in these patients is high (50–60%)3,4,7. Thus, this is a vulnerable ICU population with a continuous need for an 
organized approach to specialized care.
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Regardless of substantial development in the technology and delivery of CRRT to critically ill patients, for 
example, standardizing delivered average effluent flow rate to 20–25 ml/kg/h8, several aspects of CRRT delivery 
are not fully standardized or do not have solid evidence-based  foundations9. Outstanding questions related to 
provision of CRRT remain unanswered: patient selection, timing of CRRT initiation and discontinuation, vol-
ume management, anticoagulation and the role of high-volume hemofiltration and  hemoadsorption1,3. These 
factors hinder standardized provision of CRRT and result in wide heterogeneity of practice and in some cases, 
suboptimal care for  patients10,11. Current research focuses on addressing these uncertainties, however, informa-
tion about the delivery process and quality of CRRT is still  scarce12.
Optimal CRRT delivery demands continuous coordination and communication among multiple stakeholders, 
iterative assessment and adjustment of therapy, and quality assurance  systems11,13. A recent systematic review 
identified potential quality indicators for CRRT classified into three categories: structure, process and  outcome10, 
which included having a specialized care team, estimating the delivered and prescribed CRRT dose, measuring 
the average filter life span, evaluating patient prognosis, among  others2,10,13,14.
The success of a CRRT quality assurance system depends on team work dynamics and the selection of 
adequate CRRT metrics which can be captured longitudinally and monitored systematically to identify problems 
and generate opportunities for sustainable process  improvement11,13,15. In this quality improvement (QI) study, 
we report the development, implementation and outcomes of a quality assurance system to support the provision 
of CRRT to adult patients in the ICU.
Results
Patient characteristics. We examined our 34-month experience comprising 1185 adult patients on CRRT 
(~ 7420 patient-days of CRRT). As shown in Table 1, overall demographic and clinical data before and after 
QI interventions were comparable. There were no differences in 12 out of 13 clinical characteristics reflecting 
demographics, AKI status or acuity of illness parameters (e.g. SOFA score). The Charlson Comorbidity Index 
(CCI) was slightly lower in patients examined after the QI interventions (4.0 vs. 5.0 before the QI interventions, 
p = 0.030).
Quality improvement metrics. Data related to the selected CRRT QI metrics before and after QI inter-
ventions are shown in Table 2. To better visualize the trajectory of these metrics after the QI interventions, the 
18-month data following QI interventions were subdivided into three 6-month periods.
Table 1.  Patient characteristics before and after implementation of CRRT quality improvement interventions. 
Before QI interventions period included data from September 2016 to December 2017 (total of 16 months 
before and during QI interventions). After QI interventions period included data from January 2018 to 
June 2019 (18 months). AKI acute kidney injury, CCI Charlson comorbidity index, CRRT continuous renal 
replacement therapy, ESKD end-stage kidney disease, ICU intensive care unit, LOS length of stay, QI quality 
improvement, SOFA sequential organ failure assessment. a p-value of comparison for data before and after QI 
interventions.
Characteristics Total Before QI interventions After QI interventions p-valuea
Total patients, n (%) 1185 483 702 0.212
AKI 986 (83.2) 394 (81.6) 592 (84.3)
ESKD 199 (16.8) 89 (18.4) 110 (15.7)
Age (years), mean ± SD 56.6 ± 14.2 55.9 ± 13.9 57.1 ± 14.4 0.147
Sex, male, n (%) 712 (60.1) 290 (60.0) 422 (60.1) 0.980
Race, n (%) 0.254
White 1087 (91.7) 441 (91.3) 646 (92.0)
Black 91 (7.7) 41 (8.5) 50 (7.1)
Other 7 (0.6) 1 (0.2) 6 (0.9)
Weight (kg), median [IQR] 90.9 [75.0–109.9] 90.8 [71.0–110.0] 91.0 [77.0–109.1] 0.229
Hospital LOS (days), median [IQR] 14.6 [5.7–28.8] 14.0 [6.0–27.9] 15.1 [5.4–29.4] 0.544
ICU LOS (days), median [IQR] 8.9 [3.8–19.2] 8.6 [3.8–15.5] 9.6 [3.9–20.7] 0.072
Mechanical ventilation (days), median [IQR] 4.0 [1.0–8.0] 3.5 [1.0–7.3] 4.0 [1.0–8.0] 0.278
Total CRRT days, median [IQR] 3.1 [1.4–7.0] 3.0 [1.2–6.5] 3.3 [1.6–7.4] 0.086
SOFA score at ICU admission, median [IQR] 12.0 [9.0–14.0] 12.0 [10.0–15.0] 12.0 [9.0–14.0] 0.198
SOFA score at CRRT initiation, median [IQR] 14.0 [11.0–16.0] 13.0 [11.0–15.0] 14.0 [11.0–16.0] 0.476
CCI score, median [IQR] 4.0 [2.0–7.0] 5.0 [3.0–7.0] 4.0 [2.0–6.0] 0.030
Discharge disposition, n (%) 0.167
Alive 507 (42.8) 219 (45.3) 288 (41.0)
Dead 678 (57.2) 264 (54.7) 414 (59.0)
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Quality domain: structure. Regarding the provider subdomain, we increased our initial CRRT team from 
1 clinician champion, 1 nurse educator and 77 CRRT Super Users (ratio of Super Users to total ICU nurses: 0.13) 
in 2017 to a specialized multidisciplinary CRRT team constituted by 4 clinician champions (2 nephrologists and 
2 intensivists), 3 nurse educators, 1 CRRT QI officer, 130 CRRT Super Users (ratio of Super Users to total ICU 
nurses: 0.21), 2 dieticians, 2 physical therapists, 1 pharmacist, and 2 bioinformaticians (Supplementary Fig. S1). 
Likewise, we provided instruction to our ICU nurses and clinicians to achieve a continuum of education and 
training as detailed in Table 3.
In relation to the prescription subdomain, we improved adherence to the use of continuous veno-venous 
hemodiafiltration (CVVHDF) from 92.4% to 100% (p < 0.001). The percentage of patients using regional citrate 
anticoagulation (RCA) also significantly increased from 23.1% (January–June 2018) to 39.5% (January–June 
Table 2.  Selected CRRT metrics before and after implementation of CRRT quality improvement interventions. 
The period before QI interventions included data from September 2016 to February 2017 (6 months). CRRT 
continuous renal replacement therapy, CVVHDF continuous veno-venous hemodiafiltration, RCA regional 
citrate anticoagulation, USD United States dollars. a p-value of comparison for data before QI interventions and 
from the last 6 months after QI interventions (Jan 2019–Jun 2019). If data before QI interventions were not 
available, data from the first 6 months after QI interventions (Jan 2018–Jun 2018) were used as reference.
CRRT QI metrics Before QI interventions
After QI interventions
p-valueaJan–Jun 2018 Jul–Dec 2018 Jan–Jun 2019
CRRT modality (CVVHDF), % 92.4% 95.1% 96.6% 100.0% < 0.001
Anticoagulation (RCA), % No data 23.1% 24.7% 39.5% < 0.001
Total RCA/RCA-CRRT hours, mean ± SD No data 0.62 ± 0.30 0.68 ± 0.27 0.73 ± 0.26 0.004
Delivered effluent dose (ml/kg/h), 
mean ± SD 30.50 ± 4.18 27.67 ± 2.07 28.17 ± 1.83 30.33 ± 3.14 0.939
Delivered/prescribed effluent dose, 
mean ± SD 0.88 ± 0.07 0.88 ± 0.02 0.88 ± 0.01 0.90 ± 0.02 0.487
Filter life span (hours), mean ± SD 26.00 ± 3.16 30.17 ± 4.96 31.00 ± 2.83 31.17 ± 3.31 0.020
Filters per patient, mean ± SD 3.56 ± 0.78 2.90 ± 0.87 2.75 ± 0.50 2.67 ± 0.64 0.054
CRRT access alarms per treatment day, 
mean ± SD 2.95 ± 1.02 2.02 ± 0.64 1.63 ± 0.20 1.68 ± 0.50 0.021
Total filter cost per 100-patient (USD) ± SD 80,010 ± 17,519 65,173 ± 19,614 61,744 ± 11,287 59,876 ± 14,292 0.054
Table 3.  Summary of the three CRRT quality improvement intervention phases. CRRT continuous renal 
replacement therapy, CVVHDF continuous veno-venous hemodiafiltration, EHR electronic health records, 
ICU intensive care unit, QI quality improvement, RCA regional citrate anticoagulation.
Phase I: Team development and protocol standardization (March 2017–May 2017)
(a) Assembly of a multidisciplinary team
Nephrologists, intensivists, ICU nurses, pharmacists, dieticians, 
physical therapists, technicians, bioinformaticians, ICU managers, 
supply chain, management and administration personnel
(b) Standardization of the CRRT protocol tailoring institutional 
logistics and needs
CVVHDF modality, RCA protocol (anticoagulant citrate dextrose 
form A), customized order set (prescription entry) in the EHR; use 
of a non-tunneled temporary dialysis catheter (15–20 cm long, 12–13 
French) in the right internal jugular as the preferred CRRT vascular 
access site
Phase II: Systematic tracking of CRRT deliverables (June 2017–September 2017)
(c) Creation of electronic CRRT flowsheets
Automated data extraction from the intakes and outputs flowsheet, 
automated transfer of machine data (e.g. fluid removal, machine pres-
sures) and embedded calculations for suggested hourly fluid removal 
according to prescription
(d) Selection, monitoring and reporting of CRRT QI metrics
Ten QI metrics under 2 domains (structure and process) and 3 sub-
domains (provider, prescription and performance). Economic savings 
was also included as a QI metric
Phase III: Training and teaching (October 2017–December 2017)
(e) Enhancement of education to clinicians and ICU nurses
ICU nurse education
New user education (eighteen 4-h sessions per year) on CRRT 
prescription, protocols and technical aspects of the machine including 
circuit and filter setup, alarms management, electronic CRRT chart-
ing, among others
Super user education (six 5-h sessions per year) on CRRT deliverables 
and in-depth review of the CRRT machine, protocols and QI activities
Validator education (twelve 1-h sessions per year) on skills to verify 
CRRT competency of other ICU nurses
Clinician education
Tailored for residents, fellows and Faculty. Two introductory sessions 
and four advanced sessions per year
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2019) (p < 0.001); and from those patients, the average ratio of the hours a patient had RCA by the total hours 
the same patient was on CRRT also increased from 0.62 to 0.73 (p = 0.004). There were no data pertaining to 
the period before QI interventions for these two RCA-related QI metrics (Table 2). It is important to note that 
in our program we commonly use RCA vs. no anticoagulation for CRRT, and we seldom use systemic heparin 
unless the patient has other specific indications for systemic anticoagulation (e.g., venous thromboembolism).
Quality domain: process. When assessing the performance subdomain, the delivered CRRT effluent dose 
(ml/kg/h) remained stable (30.50 vs. 30.33; p = 0.939) as well as the ratio of delivered/prescribed CRRT effluent 
dose (0.88 vs. 0.90; p = 0.487) (Table 2). The average filter life increased from 26 to 31 h (p = 0.020), reducing 
the mean utilization of filters per patient from 3.56 to 2.67 (p = 0.054) (Fig. 1 and Table 2) despite similar CRRT 
duration (median 3.0 vs. 3.2, p = 0.194) and mortality rates (54.7% vs 56.7%, p = 0.612) when comparing the 
periods before QI interventions and the last 6 months post-intervention (January–June 2019). Also, the number 
of access alarms per treatment day was reduced by 43% (p = 0.021) (Fig. 1, Table 2).
Economic savings. The improvement in filter utilization translated into ~ 20,000 USD gross savings in filter 
cost per 100-patient receiving CRRT (p = 0.054) (Table 2, Fig. 2).
Figure 1.  Selected CRRT performance metrics before and after quality improvement interventions: (a) mean 
number of filters used per patient (blue) and mean total hours of filter life (orange); (b) mean number of CRRT 
access alarms per treatment day. CRRT continuous renal replacement therapy.
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Discussion
Critically ill patients requiring CRRT should receive their treatment in a safe, consistent and high-quality 
 manner16. Previous QI studies in the CRRT population have focused on the formation of a specialized CRRT 
 team17,18 and the creation of educational  programs19–21 to improve the provision of CRRT in the ICU. Others 
have conducted interventions to optimize specific CRRT deliverables such as the delivered effluent  dose12,17,22, 
the achievement of daily fluid removal  goals12, as well as increasing filter  life12,20,21, or decreasing unplanned filter 
 changes12 and total CRRT  downtime17,18. Our group has also reported QI interventions for patients on CRRT 
such as early rehabilitation and physical  activity23 and the management of severe hyponatremia with customized 
 solutions24. In this manuscript, we report the development, implementation and outcomes of a quality assurance 
system to support the provision of CRRT in the ICU at our institution. It is important to highlight that patient 
demographics and clinical parameters before and after the QI interventions were comparable with the only excep-
tion of the CCI score. Further, preconditions such as type of CRRT machine (Prismaflex), filter (HF1400) and 
catheter (Trialysis) remained unchanged throughout the study period, allowing the comparison of the selected 
CRRT metrics before and after QI interventions. Our report adheres to the Standards for Quality Improvement 
Reporting Excellence (SQUIRE 2.0) guidelines and  recommendations25.
The QI intervention lasted 10 months and was carried out in a step-wise fashion. Several key elements to its 
successful implementation should be noted. First, the robust multidisciplinary collaboration between nephrolo-
gists, intensivists, ICU nurses, pharmacists and other healthcare professionals provided unique perspectives, 
expertise, and helped to achieve a common mindset for the provision of CRRT in the ICU (Supplementary 
Fig. S1). Second, the standardization of the CRRT protocol on the use of CVVHDF and RCA helped to reduce 
variability of CRRT delivery and maximize the providers’ competence as education was focused on a specific 
order set. Additionally, well-defined catheter characteristics and CRRT vascular access site helped to acquire 
dexterity on its handling and functionality. Third, the creation of the electronic CRRT flowsheets allowed for 
automated machine data transfer and embedded calculations supporting data entry for ICU nurses. Furthermore, 
as this tool is available on-line within the electronic health record (EHR), the clinical and QI teams were able to 
track CRRT delivery at any given moment. Fourth, the selection, monitoring and reporting of specific CRRT QI 
metrics facilitated the assessment of interim results, identification of areas for improvement, and modifications 
or reinforcement of good practices for better outcomes. Lastly, the establishment of a dedicated CRRT education 
team made it possible to continuously train and improve the workforce’s knowledge and skills. Of note, some QI 
metrics exhibited an early trend of continuous improvement while others only showed a significant improve-
ment by the last 6 months post-implementation (e.g., use of RCA anticoagulation). The latter reflects real-world 
hindrances in CRRT delivery, which require a sustainable process of QI monitoring, continuous education, and 
tailored interventions to achieve the desired QI goals.
By the end of June 2019, we increased the number of multidisciplinary experts comprising the CRRT QI 
team and ensured a continuum of education to healthcare professionals involved in CRRT delivery. This was a 
major milestone because every CRRT program requires a diverse, strong and engaged core responsible for the 
provision of high-quality and cost-effective CRRT 11,26,27. Some institutions have described weak collaboration 
between stakeholders (e.g. nephrologists and intensivists), not enough training for their healthcare professionals 
or lack of CRRT QI  initiatives27. Fortunately, we were able to develop a specialized CRRT team in addition to 
dedicated classes for ICU nurses and clinicians held many times per year (Table 3), plus approachable educators 
to solve questions and concerns regarding CRRT delivery in a timely manner.
Regarding CRRT modality and anticoagulation, we were able to improve consistency of care and reduce 
CRRT variability by standardizing the CRRT protocol according to our local logistics and expertise. We achieved 
Figure 2.  Gross filter cost per 100-patient receiving CRRT before and after quality improvement interventions.
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100% CVVHDF use, ~ 40% RCA use with > 70% of the CRRT time on RCA by the end of the study period. No 
other form of anticoagulation is routinely used when performing CRRT in our program unless the patient has 
specific indications for systemic anticoagulation. Even though we increased the CVVHDF use to the maximum, 
adherence to the citrate protocol should be further improved as evolving evidence suggests prolonged filter life 
span with RCA  use28–31. Challenges to widespread implementation of RCA use may be related to patient-specific 
factors (e.g., impaired liver metabolism under certain shock scenarios), feasibility of protocols for citrate titration 
and calcium supplementation, and clinician and nursing staff logistics and training. Furthermore, one should 
note that there is no evidence to support any specific CRRT modality over the other but reducing practice vari-
ability may prevent operator-related errors and therefore we selected a single modality of CRRT (e.g., CVVHDF) 
for our program.
CRRT dose is a dynamic metric that must be adjusted to the changing clinical needs of the  patient9. Accord-
ing to Kidney Disease Improving Global Outcomes (KDIGO), it is recommended to achieve a delivered average 
CRRT effluent flow rate of 20–25 ml/kg/h, but ~ 30 ml/kg/h could be prescribed as interruptions, the use of pre-
filter solutions and reductions in membrane permeability decrease the delivered  dose8. Furthermore, the Acute 
Disease Quality Initiative (ADQI) group stated the average ratio of the effective delivered effluent dose relative 
to prescribed dose should be > 0.8032. Our results showed that the delivered CRRT effluent dose (~ 30 ml/kg/h) 
and the delivered/prescribed effluent dose ratio (~ 0.89) did not significantly change after QI interventions and 
remain adherent to guideline recommendations.
In relation to filter life, we managed to increase it from 26 to 31 h and decrease mean utilization of filters 
per patient from 3.56 to 2.67 despite no change in CRRT duration or mortality rates. Current evidence suggests 
optimization of circuit patency and filter performance primarily depends on anticoagulation practices (favor-
ing RCA use)30,31, but there are still insufficient data to determine if preconditions (filter, vascular access site, 
catheter type) or patient characteristics (mechanical ventilation, SOFA score, calcium levels, platelet count, red 
blood cell transfusion, fibrinogen) may alter filter  life33. Likewise, education to ICU nurses about filter manage-
ment appears to increase its life  span20,21, but evidence is still limited and more research is  needed33. Therefore, 
it is important to document reasons for filter change and evaluate filter life span accordingly. As described by 
Mottes et al., there are planned filter changes (e.g., filter expiration, decision to stop therapy) and unplanned filter 
changes (e.g., cardiac arrest, emergent test or procedure, clotted circuit)20. We are currently working to improve 
our data collection to better examine specific reasons of filter change.
With respect to the number of access alarms per treatment, we reduced them by 43%. Although we did not 
assess for correlation with access placement site due to data availability, we hypothesize this could be a result of 
the iterative instruction to clinicians on proper catheter election and placement, in addition to enhanced educa-
tion for ICU nurses on access alarm recognition, management and resolution.
The cost of CRRT relies on ICU nurse staffing salary, dialysate and/or replacement fluids, anticoagulation and 
extracorporeal circuit (including filter)  costs34. It was estimated that a 24-h CVVHDF treatment costs ~ $1060 
USD (excluding anticoagulation), but prices may vary from center to  center35. After the described CRRT QI 
interventions, we improved our resource utilization (average filter life span and average total number of filters 
used per patient) and rendered ~ 20,000 USD gross savings in filter cost per 100-patient receiving CRRT at our 
institution. It is important to emphasize that these savings are only related to filter cost and does not account for 
other CRRT-related costs such as fluids, anticoagulation, monitoring or staffing salary.
Our study has some limitations to consider when interpreting the results. First, given the multifaceted quality 
assurance implementation, we cannot prove which specific QI intervention impacted any given outcome (e.g., 
RCA use vs. nurse education for improvement in filter life). Further, residual confounding is possible given the 
observational nature of this QI study. Second, this work was primarily planned to improve CRRT local care 
according to the characteristics and logistics of our institution, therefore our approach may not be applicable to 
other centers. Likewise, additional monitoring may be necessary to evaluate the sustainability of these results 
over time. However, we established a framework for quality assurance, analyzed a large number of patients 
(~ 7420 patient-day of CRRT) and made several measurements of CRRT QI metrics accepted in our scientific 
community to compare outcomes before and after QI interventions. Future directions include expanding our 
data collection to have additional tracking of CRRT QI metrics (e.g. intended vs. unintended filter changes, 
medication adjustments, fluid management, small solute clearance, adverse events, catheter dysfunction) as 
proposed by Rewa et al.16 and  others12–14. Finally, this work exemplifies the ability to nurture collaborative and 
quality improvement work in the ICU.
Our findings indicate that through developing a multidisciplinary CRRT team, standardizing CRRT proto-
cols, integrating machine/EHR data, and reinforcing education, we were able to improve adherence to protocols, 
confidently and sustainably track CRRT delivery and reduce filter resource utilization at our institution. Addi-
tional studies are needed to confirm these results and the impact of these QI initiatives on processes of care and 
patient-centered outcomes.
Methods
Setting. The University of Kentucky (UK) Albert B. Chandler Hospital is a 945-bed acute care hospital with 
more than 37,000 admissions and approximately 2500 medical ICU admissions per  year23,24. The Nephrology 
ICU consultation team (consisting of one attending, one fellow, and one resident or advanced practitioner) 
provides diagnostic and therapeutic services for patients with AKI and ESKD requiring CRRT in the ICU. The 
provision of CRRT leans on a multidisciplinary approach, including intensivists, ICU nurses, pharmacists and 
many other specialists. We perform CRRT for approximately 500 patients annually, corresponding to ~ 3200 
CRRT patient-day per year.
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This QI study describes the development, implementation and outcomes of a quality assurance system to 
support the provision of CRRT to adult patients in the ICU. This QI study was approved by the University of 
Kentucky Institutional Review Board (IRB) of the Office of Research Integrity (17-0444-P1G). Requirement for 
informed consent was waived by the IRB (https ://www.resea rch.uky.edu/offic e-resea rch-integ rity). All methods 
were carried out in accordance with relevant guidelines and regulations.
Implementation. We developed and implemented a quality assurance system using a step-wise approach in 
3 phases (intervention period, total of 10 months) (Fig. 3). The Phase I (3 months) consisted in the (a) assembly 
of a multidisciplinary team and the (b) standardization of the CRRT protocol tailoring institutional logistics and 
needs. The Phase II (4 months) involved the (c) creation of electronic CRRT flowsheets (Supplementary Fig. S2) 
and the (d) selection, monitoring and reporting of CRRT quality metrics. Finally, the Phase III (3  months) 
focused on the (e) enhancement of education to clinicians and ICU nurses.
We also established 3 study periods with the purpose of evaluating the impact of our intervention (Fig. 3). 
These periods were defined according to data availability before the intervention and the step-wise completion 
of milestones during the intervention phases. These periods consisted of: (1) before intervention (September 
2016 to February 2017, 6 months); (2) intervention (March 2017 to December 2017, 10 months); and (3) after 
intervention (January 2018 to June 2019, 18 months).
Intervention. The 10-month intervention was carried out from March 2017 to December 2017 in 3 step-
wise phases described in Table 3. Team development and protocol standardization (Phase I) allowed the estab-
lishment of the multidisciplinary quality assurance team (Supplementary Fig. S1) which reached consensus for 
CRRT protocols (modality, dose, access, and anticoagulation) based on revision of current guidelines, evidence-
based practices, institutional logistics and local expertise. For the selection of CRRT QI metrics to monitor 
CRRT delivery (Phase II), we adapted via consensus the quality control system proposed by Joannes-Boyau 
et al.13 including structure metrics encompassing the CRRT provider (e.g., specialized team, education program) 
and the CRRT prescription (e.g. modality, prescribed dose, anticoagulation); and process (performance) metrics 
(e.g., delivered dose, filter life span, access alarms). A total of 11 CRRT QI metrics (study outcomes) under the 
domains of structure and process, and 3 subdomains (provider, prescription and performance) in addition to 
economic savings specific to filter use were selected for this study and are described in detail in Table 4. Precon-
ditions such as type of CRRT machine, filter and catheter were not changed throughout the study period. For 
training and teaching (Phase III), we conducted dynamic monthly assessments of learning needs to tailor teach-
ing activities for ICU nurses (New and Super Users) and clinicians. This was done by auditing CRRT charting, 
assessing machine specific performance data, and making rounds in the ICUs (Super Users were available in 
both day and night shifts). Clinical duties were not compromised as the QI officer and leadership of the program 
have protected time for these activities. Furthermore, physicians, ICU nurses and other healthcare professionals 
were invited to attend bi-monthly QI meetings in order to voice all concerns they were experiencing as well as to 
conduct an iterative assessment of the program.
Study data. Data from all adult patients (≥ 18 years old) receiving CRRT in the ICU during the study period 
were analyzed. Demographic and clinical data were collected by automated digital extraction from the EHRs 
through a flexible dashboard (Tableau, Supplementary Fig. S3), which allowed data to be downloaded as spread-
sheets or graphics for review and further analysis. Data extraction was validated through individual review of 
EHRs. Performance data from CRRT machines were extracted from accessing individual machine data cards 
during the study period.
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Statistical analysis. Categorical variables are expressed as counts and percentages. Continuous variables 
are reported as mean and standard deviation (SD), or median and interquartile range (IQR) according to data 
distribution. A chi-square test or Fisher’s exact test was used to compare categorical variables when appropri-
ate. Continuous variables with a normal distribution were compared using an independent Student t-test; in 
contrast, variables not exhibiting a normal distribution were compared using the Mann–Whitney U test. All 
statistical analyses were performed using SPSS 24.0 (IBM SPSS Statistics for Windows, Version 24.0. Armonk, 
NY: IBM Corp). A two-tailed p < 0.05 was considered statistically significant.
Ethics approval and consent to participate. This QI study was approved by the University of Kentucky 
Institutional Review Board (IRB) of the Office of Research Integrity (17-0444-P1G). Requirement for informed 
consent was waived by the IRB (https ://www.resea rch.uky.edu/offic e-resea rch-integ rity). All methods were car-
ried out in accordance with relevant guidelines and regulations.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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